Application of Lipid-modulating Agents in the Dialysis Patients with End-stage Renal Disease
10.3969/j.issn.1008-049X.2017.09.027
- VernacularTitle:调脂药在终末期肾脏病透析中的应用
- Author:
Qianqian FAN
;
Jie MA
- Keywords:
End-stage renal disease;
Dialysis;
Lipid-modulating agents
- From:
China Pharmacist
2017;20(9):1618-1622
- CountryChina
- Language:Chinese
-
Abstract:
Although dyslipidemia is common in the patients with end-stage renal disease undergoing dialysis, it is still controver-sial in the efficacy and safety of lipid-modulating agents used in the patients. In this paper, current large-scale randomized controlled trials and observational studies were reviewed, and the influence and characteristics of dyslipidemia as well as the application of com-mon lipid-modulating agents in dialysis patients were summarized. The current clinical evidence suggested that the use of statins with or without ezetimibe could effectively reduce the level of blood lipid in dialysis patients without increased risk of adverse events, while it had limited role in cardiovascular protection;fibrates had higher risks in dialysis patients; nicotinic acids had limited use mainly be-cause of their unbearable side effects.
